Latest news with #NestléHealthScience
Yahoo
3 days ago
- Business
- Yahoo
$1.2 bN Human Microbiome-based Drugs and Diagnostics Global Markets, 2022-2024 & 2025-2030
The human microbiome-based drugs and diagnostics market is projected to grow from $393.4M in 2025 to $1.2B by 2030, at a CAGR of 25.6%. Key players include Ferring, Nestlé Health Science, and Vedanta Biosciences. The report covers market trends, competitive landscape, and ESG developments. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Human Microbiome-based Drugs and Diagnostics: Global Markets" report has been added to global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030. The report discusses emerging technologies and analyzes the competitive landscape, providing the ranking/market shares of leading companies in the market. It also includes a chapter on environmental, social and corporate governance (ESG) microbiome-based drugs and diagnostics are novel approaches to tackling difficult-to-treat diseases. The growing understanding of the human microbiome can be leveraged to fill the gaps in conventional treatment options. A wide range of scientific studies have demonstrated the role of microbiomes in the pathogenesis of various diseases. The microbiome field is also witnessing an increased level of investments from the private and public sectors. Future opportunities in the market lie in exploring microbiomes in other body parts, such as lungs, and developing microbiome-based drugs as combination therapies. Leading companies in the market for human microbiome-based drugs and diagnostics include Ferring, Nestle Health Science (Seres Therapeutics), BiomeBank, Genetic Analysis AS and Vedanta Scope 55 data tables and 51 additional tables Analyses of the trends in global markets for human microbiome-based drugs and diagnostics, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030 Estimates of the size and revenue prospects for the global market, along with a market share analysis by type, drug route of administration, diagnostics product type, application, end user, and region Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables Review of the prevalence of infectious diseases, metabolic disorders and chronic ailments An assessment of current products, clinical trials and identification of new potential markets for novel products and assay development Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes An analysis of the key patent grants and recently published patents Analysis of the industry structure and value chain, and the competitive landscape, including companies' market shares, strategic alliances, M&A activity, venture fundings and investment outlook Profiles of the leading companies, including Ferring Pharmaceuticals, Nestle Health Science, BiomeBank, Genetic Analysis AS, and Vedanta Biosciences Inc. Companies Featured BiomeBank EnteroBiotix Ltd. Enterome Ferring Genetic Analysis Illumina Inc. Microbiome Insights Microbiotica Nestle Health Science Oxford Nanopore Technologies plc PacBio SFA Therapeutics Inc. Thermo Fisher Scientific Inc. Vedanta Biosciences Inc. Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Market Dynamics Emerging Technologies Analysis by Segment Regional Analysis Conclusion Chapter 2 Market Overview Overview and Market Definition Different Microbiomes in Humans Microbiome, Human Health and Disease Technologies Aiding Microbiome Research Culturing and Cultivation Strategies for the Development of Microbiome Therapeutics Additive Microbiome Therapy Modulatory Microbiome Therapy Analysis of Macroeconomic Factors Geopolitical Factors Inflation and Currency Exchange Fluctuations Porter's Five Forces Analysis Chapter 3 Market Dynamics Takeaways Market Drivers Growing Evidence of Microbiome-disease Correlation Microbiome-based Diagnostics for Disease Prevention and Monitoring Market Restraints Challenges in Clinical Trial Design Lack of Established Regulatory Frameworks High Costs of Microbiome Therapeutics Market Opportunities Direct-to-Consumer Microbiome Testing Drugs and Diagnostics for Lung and Skin Microbiomes Chapter 4 Regulatory Landscape Regulatory Aspects North America Europe Asia-Pacific Chapter 5 Emerging Technologies Takeaways Emerging Technologies Microbial Ecosystem Therapeutics Metatranscriptome Sequencing Genetically Modified Microbiome Therapeutics Combination and Adjuvant Therapies with Microbiome-based Drugs Novel Preclinical Models Chapter 6 Market Segmentation Analysis Segmentation Breakdown Market Analysis by Type Microbiome-based Drugs Market Analysis by Application Infectious Diseases GI Disorders Metabolic Disorders Cancer Other Diseases Market Analysis by End User Hospitals and Clinics Research Institutions Pharmaceutical Companies Geographic Breakdown Market Analysis by Region North America Europe Asia-Pacific South America Middle East and Africa Chapter 7 Competitive Intelligence Takeaways Company Share Analysis Competitive Analysis Venture Funding and Investment Landscape Recent Developments Chapter 8 Sustainability in the Human Microbiome-based Drugs and Diagnostics Industry: An ESG Perspective Introduction to ESG ESG Risk Ratings Concluding Remarks Chapter 9 Appendix For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Business Upturn
24-04-2025
- Business
- Business Upturn
Global earnings: Nestle Q1 organic revenue rises 2.8% YoY, surpassing estimated 2.57%
By Aditya Bhagchandani Published on April 24, 2025, 10:46 IST Nestlé has kicked off 2025 with a resilient performance despite macroeconomic and consumer headwinds, reporting organic sales growth of 2.8% year-on-year in the first quarter, ahead of analyst expectations pegged at 2.57%. The company posted a Real Internal Growth (RIG) of 0.7% and pricing growth of 2.1%, signaling continued traction in both volume and value amid inflation and shifting consumer behavior. CEO Laurent Freixe commented, 'In an environment of heightened macroeconomic and consumer uncertainty, Nestlé delivered organic growth of 2.8%, with broad-based performance across markets and categories and improving share trends, especially in our billionaire brands.' Q1 2025 financial performance: Highlights Growth was broad-based, with Zone AOA (Asia, Oceania, and Africa) delivering 3.1% organic growth, and Nestlé Waters & Premium Beverages growing by 3.6%. The highest growth rate was seen in the 'Other Businesses' division at 6.4%. Notably, confectionery and coffee categories led organic growth with 8.9% and 5.1%, respectively, powered largely by price hikes to offset input cost pressures. Segment performance snapshot Nestlé Health Science reported 4.2% organic growth but experienced mixed performance across geographies. Nespresso rose 5.7% organically, showing signs of rebound. PetCare, despite softness in the U.S. market, grew 1.6% and continued gaining market share in several countries. Strategic and operational update Nestlé is actively advancing its 'Fuel for Growth' program, targeting CHF 0.7 billion in incremental cost savings by 2025. So far, savings have primarily been achieved through procurement efficiencies. Key strategic initiatives included: Big bet innovations : Successful roll-outs of Nescafé Espresso Concentrate , pyramid-shaped gourmet cat food, and new Chocobakery products across Latin America and AOA. Improved business cells : 18 underperforming segments are being actively restructured, showing early signs of turnaround. Organizational simplification: Especially in Zone Europe, where Nestlé is harmonizing its structure to boost efficiency and innovation pace. Freixe added, 'We are continuing to make changes throughout the organization to increase alignment and focus, and strengthen our R&D capabilities.' 2025 guidance remains intact Despite global uncertainties and evolving tariff dynamics, Nestlé has reaffirmed its full-year 2025 guidance: Organic sales growth is expected to improve vs 2024 and accelerate through the year . UTOP margin is projected at or above 16%, reflecting continued investments in growth. Nestlé remains cautious but confident in navigating a dynamic environment shaped by tariffs, commodity volatility, and FX pressure, while reinforcing its long-term goal of value-driven growth and market leadership. FAQs What drove Nestlé's Q1 2025 revenue beat? Pricing actions in coffee and cocoa, along with a moderate rebound in volume growth and innovation-led product launches. Which categories posted the strongest growth? Confectionery (+8.9%) and Coffee (+5.1%), primarily driven by pricing. What is Nestlé's 2025 margin guidance? UTOP margin is expected to be at or above 16%, unchanged from prior guidance. What is the outlook for the rest of the year? Organic growth is projected to accelerate in the second half, supported by innovation, cost savings, and operational restructuring. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Markets are subject to risk. Please consult a professional financial advisor before making investment decisions. Business Upturn and its authors are not liable for any losses arising from the use of this information. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
